Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh

Phase 3positiveolatorepatidumPositive

AI Analysis

Summary

Hansoh presented Phase 3 trial results for olatorepatidum demonstrating 19.3% weight loss at 48 weeks in a weight management study at the 2026 EASD annual meeting in Milan.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

19.3% weight loss at week 48

Importance:7/10

Sentiment:

0.70

obesityweight_managementdiabetesEASD_2026Chinalate_breaking_abstract

Related Companies

$HNPHY

Read the original article

Published by PR Newswire Biotech on October 2, 2026 12:08 PM

Read Original